PDS Biotechnology shares soared in their best session in two months after the firm sought an FDA meeting for an accelerated approval of its cancer drug, PDS0101. The company aims to amend its Phase 3 trial to include progression-free survival as a primary endpoint. Retail traders on Stocktwits turned bullish, betting on early approval and calling the stock too cheap.